#USA #San Diego #Clinical Data #Sanguine Biosciences #Biospecimen

Sanguine Biosciences Expands Clinical Biospecimen Portfolio

Sanguine Biosciences, a prominent provider in the field of human biospecimens and real-world clinical data, has recently announced significant expansions to its clinical sample offerings. With the introduction of two new sample types - Synovial Fluid and Skin Punch Biopsy collections - the company is elevating its potential to assist researchers in exploring complex processes behind autoimmune and dermatological disorders.

Enhancing Research on Autoimmune and Inflammatory Disorders

The new Synovial Fluid offering allows researchers to access fresh, high-quality fluid collected from individuals suffering from various inflammatory joint diseases, such as rheumatoid arthritis, psoriatic arthritis, and gout. This resource provides critical clinical metadata, including disease duration, treatment history, and relevant clinical tests, which is essential for bridging molecular signatures with clinical phenotypes.

Key Features:

• - Fresh or frozen synovial fluid obtained under sterile conditions.
• - Disease-specific donor recruitment for conditions like RA and gout.
• - Optional matching of whole blood, serum, and other samples.
• - All procedures are IRB-approved and compliant with HIPAA regulations.

Gerald Lee, the Chief Product Officer at Sanguine Biosciences, emphasized the importance of these samples, stating that “access to high-integrity synovial fluid provides a direct window into inflammatory biology,” marking a leap forward for research into cytokine profiles and immune cell interactions in joint diseases.

Pioneering Skin Punch Biopsy for Dermatological Research

In addition to synovial fluid, Sanguine is introducing skin punch biopsy offerings targeting diverse areas such as psoriasis, atopic dermatitis, and scleroderma. These biopsies enable a deeper level of understanding regarding immune pathways and structural changes in affected tissues.

Product Highlights:

• - 2mm to 3mm diameter skin punch biopsies available from both disease and healthy control sites.
• - EMR-verified and comprehensive clinical metadata to ensure reliability.
• - Options for fresh or frozen tissue based on research requirements.
• - Samples have prospectively collected history which aligns with protocol needs.

According to Lee, dermatology researchers need tissue-level insights that can’t be captured through peripheral blood samples alone. These punch biopsies offer invaluable tools for investigating immune factors directly within the affected tissues.

Commitment to Convenient and Effective Clinical Research

Both offerings reflect Sanguine's dedication to facilitating clinical research through accessible, community-focused participation. The company has created a streamlined digital platform that allows for digital consent at the point of care, ensuring engagement without additional operational demands for clinics and patients.

By integrating clinical data with rich biospecimen profiles, including EMR histories and longitudinal sampling options, Sanguine enables researchers to compile extensive datasets that support significant advancements in understanding autoimmune and inflammatory diseases.

About Sanguine Biosciences

Established as a leading source of high-quality biospecimens and clinical data, Sanguine Biosciences uses a nationwide participant-centric network to empower pharmaceutical and biotech organizations. With IRB-approved protocols and a commitment to community engagement and real-time coordination, Sanguine facilitates translational research across a wide array of health areas, including oncology, autoimmune, and rare diseases.